French president Macron seeks meeting after Sanofi CEO's vaccine comments

Emmanuel Macron
French president Emmanuel Macron is seeking a meeting with Sanofi after the company's CEO said the U.S. would get early access to COVID-19 vaccines. (

That was fast. Less than a day after Sanofi CEO Paul Hudson said the U.S. would be set for first dibs on the company’s potential COVID-19 vaccine, pushback is mounting, and French President Emmanuel Macron wants a meeting. 

Following Hudson’s assertion that the U.S. would get initial access to Sanofi’s COVID-19 vaccine program—if it succeeds—France's junior economy minister Agnes Pannier-Runacher told Sud Radio that “privileged access” for various countries would be “unacceptable,” Reuters reports. Sanofi is based in Paris and has operations worldwide.

Macron himself was “affected” by the news and is seeking a meeting, a government official told Bloomberg. A potential vaccine would need to benefit the “common good,” the official added. 


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

The pushback comes after Hudson told Bloomberg the United States’ early investment into Sanofi’s program means the country “has the right to the largest pre-order.” Hudson has served as Sanofi's CEO since September, joining from Swiss drug giant Novartis.

The U.S. government expects early access, Hudson told the news service. The U.S. backed Sanofi’s project back in February, and as part of the deal, the government expects that “if we’ve helped you manufacture the doses at risk, we expect to get the doses first,” Hudson told Bloomberg. 

RELATED: Sanofi CEO: Upfront funding wins U.S. first access to coronavirus shot 

Shortly after the remarks made their rounds, Sanofi press representatives sought to clarify the picture. A spokesman said the company "benefits from a diversified footprint around the world" and has "always been committed in these unprecedented circumstances to make our vaccine accessible to everyone." 

Vaccines made in the U.S. will be designated for U.S. use, he said, while other sites will supply Europe and the rest of the world. 

As vaccine programs race forward, there’s “no guarantee” any will work, NIAID chief Anthony Fauci said at a Senate hearing this week. Still, he's "cautiously optimistic," and experts are already thinking about access and supply concerns.  

RELATED: With capacity stretched and billions of doses required, COVID-19 vaccine makers cheer each other on 

Stephane Bancel, the CEO of Moderna, said at a recent CNBC virtual summit that he hopes “three, four, five vaccines” against COVID-19 succeed, “because no manufacturer can make enough doses for the planet.” 

Moderna is among several companies that have inked partnerships to build capacity ahead of potential launches. Johnson & Johnson has struck a pair of deals, while Sanofi and GlaxoSmithKline partnered to combine their global scale. AstraZeneca has signed on to develop and produce promising vaccines from a project led by the University of Oxford. Pfizer is working to scale up with BioNTech, its development partner.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.